International Stem Cell to sell Lifeline Cell Technology to ATCC for $25 million
ISCO•Deal terms, timing and closing conditions
Cash at closing will be reduced by a $2.6 million escrow, including $2.5 million for indemnities and $100,000 for adjustments.
Closing is targeted for the third fiscal quarter of 2026, subject to customary conditions and a post-close working-capital true-up.
Majority holders have signed support agreements to vote in favor of the transaction. The seller faces non-solicitation limits before closing and five-year post-close restrictions.
International Stem Cell agrees to sell Lifeline Cell Technology
International Stem Cell Corporation agreed to sell Lifeline Cell Technology to American Type Culture Collection for $25 million, subject to closing adjustments.
The deal transfers 100% of Lifeline’s membership interests. The business supplies primary human cells, stem cells, and related research reagents.
